Related Experiment Video
Updated: Oct 1, 2025
Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy
Yi-Fan Chen1,2, Chien-Huang Wu3, Li-Hsien Chen1
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan, R. O. C.
Abstract:
Chemotherapy-induced neurotoxicity is a common adverse effect of cancer treatment. No medication has been shown to be effective in the prevention or treatment of chemotherapy-induced neurotoxicity. Using minoxidil as an initial template for structural modifications in conjunction with an in vitro neurite outgrowth assay, an image-based high-content screening platform, and mouse behavior models, an effective neuroprotective agent CN016 was discovered. Our results showed that CN016 could inhibit paclitaxel-induced inflammatory responses and infiltration of immune cells into sensory neurons significantly. Thus, the suppression of proinflammatory factors elucidates, in part, the mechanism of action of CN016 on alleviating paclitaxel-induced peripheral neuropathy. Based on excellent efficacy in improving behavioral functions, high safety profiles (MTD > 500 mg/kg), and a large therapeutic window (MTD/MED > 50) in mice, CN016 might have great potential to become a peripherally neuroprotective agent to prevent neurotoxicity caused by chemotherapeutics as typified by paclitaxel.
Insights
A novel neuroprotective agent, CN016, effectively prevents chemotherapy-induced neurotoxicity by inhibiting inflammatory responses. This discovery offers hope for managing peripheral neuropathy caused by cancer treatments like paclitaxel.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Chemotherapy-induced neurotoxicity is a significant challenge in cancer care, lacking effective preventative or therapeutic options.
- Paclitaxel, a common chemotherapeutic, can cause debilitating peripheral neuropathy.
- Current treatments for chemotherapy-induced neurotoxicity are limited.
Purpose of the Study:
- To discover and characterize a novel neuroprotective agent for chemotherapy-induced neurotoxicity.
- To investigate the mechanism of action of the identified agent against paclitaxel-induced neurotoxicity.
- To evaluate the efficacy and safety of the agent in preclinical models.
Main Methods:
- Utilized minoxidil as a structural template for modifications.
- Employed an in vitro neurite outgrowth assay and high-content screening.
- Validated findings using mouse behavior models and assessment of inflammatory responses.
Main Results:
- Discovered CN016, a potent neuroprotective agent.
- CN016 significantly inhibited paclitaxel-induced inflammatory responses and immune cell infiltration.
- Demonstrated suppression of proinflammatory factors as a key mechanism of action.
- CN016 showed excellent efficacy in improving behavioral functions in mice.
- CN016 exhibited a high safety profile with a large therapeutic window (MTD/MED > 50).
Conclusions:
- CN016 effectively alleviates paclitaxel-induced peripheral neuropathy by suppressing inflammatory pathways.
- The agent demonstrates significant potential as a peripherally neuroprotective agent for cancer patients.
- CN016 offers a promising therapeutic strategy to mitigate neurotoxicity from chemotherapeutics like paclitaxel.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:24Local Anesthetics: Differential Sensitivity of Nerve Fibers